This excerpt taken from the SSRX 20-F filed Apr 21, 2009.
B. Related Party Transactions
Certain agreements with VIE entities
See 4.C.2 Economic and Control Arrangements for certain agreements with VIE entities.
Agreements with Epitomics Inc.
The collaboration partner for our development of TNF alpha monoclonal antibody, Epitomics Inc., or Epitomics, is a related party, whose Chief Executive Officer is an immediate family member of our Chief Scientific Officer. The collaboration combines our development capabilities and Epitomics approach for generating a large panel of therapeutic leads for the purpose of the identification of best-in-class drug candidates for anti-TNF therapy. There were no fees paid to Epitomics during fiscal 2008. Under the terms of the agreement, Epitomics may receive royalties on any potential future products sold in China.
This excerpt taken from the SSRX 20-F filed Jun 27, 2008.
19 Related party transactions
This excerpt taken from the SSRX 20-F filed Jun 29, 2007.
4.3 Related Party Transactions
The Company is required to describe any transaction, since the beginning of its last fiscal year, or any currently proposed transaction, in which the Company was or is to be a participant and in which any related person had or will have a direct or indirect material interest.
All employees must provide the following disclosure with respect to each related person transaction:
Related persons are defined to include directors, executive officers, nominees for the board (if information is being presented in a proxy statement), beneficial owners of 5% or more of any class of the companys voting securities, and their immediate family members. Immediate family members include children, stepchildren, parents, stepparents, spouses, siblings, parents-in-law and siblings-in-law, and any person sharing the household of the director, executive, nominee, or shareholder, other than tenants and employees.